All six vaccinated macaques remained completely healthy.
VSV-SUDV vaccine completely protected vaccinated macaques while four of five unvaccinated controls developed Sudan virus disease after lethal challenge. Sudan virus, identified in 1976, caused 142 cases and 55 deaths in Uganda's 2023 outbreak; currently no licensed treatment or vaccine exists for this deadly pathogen.
- VSV-SUDV vaccine completely protected all 6 vaccinated macaques; 4 of 5 unvaccinated controls developed Sudan virus disease
- Sudan virus outbreak in Uganda (2023): 142 confirmed cases, 55 deaths over four months
- Sudan virus identified in 1976; currently no licensed vaccine or treatment exists
- VSV-SUDV based on Ervebo platform, approved by FDA and EMA in 2019 for Ebola
NIH researchers successfully developed VSV-SUDV, an experimental vaccine based on the licensed Ebola vaccine, achieving complete protection against lethal Sudan virus in primate trials.
Researchers at the National Institute of Allergy and Infectious Diseases have engineered a vaccine against Sudan virus, one of the deadliest pathogens known to medicine, and demonstrated its complete effectiveness in protecting primates from lethal infection. The vaccine, called VSV-SUDV, builds on technology that produced Ervebo, the first approved Ebola vaccine, by swapping out the Ebola protein for its Sudan virus equivalent and delivering it through a genetically modified animal virus.
Sudan virus emerged in 1976 and remains one of four known human ebolavirus pathogens. It is less frequently encountered than Ebola but equally lethal. In late 2022 and early 2023, Uganda experienced a four-month outbreak that confirmed 142 cases and killed 55 people before ending in January. Despite the virus's severity and periodic reappearance, no licensed treatment or vaccine has existed until now—though several candidates are moving through clinical and preclinical development stages.
The NIH team's approach uses vesicular stomatitis virus, an animal pathogen that primarily infects cattle, as a delivery vehicle. The researchers engineered it to carry and express a key Sudan virus protein, creating a single-dose vaccine. This strategy mirrors the one that led to Ervebo's approval by European and American regulators in 2019. The new vaccine candidate follows the same proven pathway.
To test safety and effectiveness, the scientists vaccinated six cynomolgus macaques with VSV-SUDV and compared them against five control animals that received VSV-MARV, an experimental vaccine for Marburg virus. All animals had previously received an Ebola vaccine and waited nine months before the trial began. Over the following month, neither group showed adverse reactions. Then came the critical test: researchers exposed all eleven animals to a lethal dose of Sudan virus.
The results were stark. All six vaccinated macaques remained completely healthy. Four of the five control animals developed clinical signs of Sudan virus disease. One control animal survived without symptoms, which surprised the research team and prompted them to plan additional studies into possible cross-protective immune responses between the two viruses.
The outcome of the control group proved an important point: prior exposure to Ebola virus and the Ebola vaccine offered minimal protection against Sudan virus. The two pathogens, while related, are distinct enough that immunity to one does not reliably shield against the other. This finding underscores why a Sudan-specific vaccine was necessary.
The researchers published their findings in The Lancet Microbe and now anticipate moving toward human trials. They expect that VSV-SUDV, administered at doses similar to those used for Ervebo, would generate rapid protective immunity in people. The path from animal studies to licensed vaccine remains long, but the primate data provides a solid foundation. For a virus that has killed dozens in recent months and could strike again, the development represents a meaningful step toward preparedness.
Notable Quotes
The fact that four control animals got sick demonstrates that pre-existing immunity to EBOV and VSV-EBOV has limited effect on protection from SUDV.— NIH research team
The Hearth Conversation Another angle on the story
Why does Sudan virus need its own vaccine if we already have one for Ebola?
Because immunity to Ebola doesn't protect you from Sudan virus. They're related—both ebolaviruses—but genetically distinct enough that your immune system trained on one doesn't recognize the other. The control animals in this study had Ebola immunity and still got sick.
So the researchers just took the Ebola vaccine and swapped out one protein?
Essentially, yes. They used the same proven delivery system—a modified animal virus—but replaced the Ebola protein with Sudan's equivalent. It's elegant because they didn't have to invent the whole platform from scratch. Ervebo already works and is approved, so they knew this approach could work.
What surprised them about the one control animal that didn't get sick?
That's the mystery. One unvaccinated macaque exposed to lethal Sudan virus didn't develop disease, even though four others did. It suggests there might be some cross-protective response they don't yet understand. They're planning more studies to figure out what happened.
How quickly could this move to human use?
That depends on regulatory pathways and clinical trials. The animal data is compelling—complete protection is a strong signal. But they'll need to test it in people first, establish safe dosing, confirm the immune response. Given that Ervebo already exists and is approved, the regulatory framework is clearer than it would be for a completely novel vaccine.
Does this mean the next Sudan outbreak could be prevented?
Not immediately. This is still experimental. But it means the tools exist now. If the virus emerges again before VSV-SUDV is licensed, at least we know a vaccine can work. That's different from the Uganda outbreak, where there was nothing.